Neurocrine Biosciences Inc (NBIX) — 10-Q Filings
All 10-Q filings from Neurocrine Biosciences Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Neurocrine's Q3 Net Income Soars 61% on Strong Product Sales
— Oct 28, 2025 Risk: medium
NEUROCRINE BIOSCIENCES INC (NBIX) reported a strong financial performance for the three months ended September 30, 2025, with total revenues increasing to $794. -
Neurocrine's Q2 Sales Surge, Collaboration Revenue Doubles
— Jul 30, 2025 Risk: medium
NEUROCRINE BIOSCIENCES INC reported a significant increase in product sales for the three months ended June 30, 2025, reaching $510.0 million, up from $430.0 mi -
Neurocrine Biosciences Q1 2025 Update
— May 5, 2025 Risk: low
Neurocrine Biosciences Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial filings indicate a fiscal year end of Decemb -
Neurocrine Biosciences Files Q3 2024 10-Q Report
— Oct 30, 2024 Risk: low
Neurocrine Biosciences, Inc. (NBIX) filed its quarterly report for the period ended September 30, 2024. The company is incorporated in Delaware and headquartere -
Neurocrine Biosciences Q2 2024 Update
— Aug 1, 2024 Risk: medium
Neurocrine Biosciences Inc. reported its financial results for the period ending June 30, 2024. The company's filing indicates ongoing operations in the biologi -
Neurocrine Biosciences Inc. Files 10-Q for Period Ending March 31, 2024
— May 1, 2024 Risk: low
NEUROCRINE BIOSCIENCES INC (NBIX) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Revenue for the three months ended March 31, 2024, was $453 milli
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX